17 April 2014 - Medac Pharma, a United States-based pharmaceutical company, has received approval from the US Food and Drug Administration for the name, Rasuvo, for its lead compound, MPI-2505, a subcutaneous injectable methotrexate delivered in a ready-to-use autopen, it was reported yesterday.

The product is being developed for multiple indications, including rheumatoid arthritis, poly-articular-course juvenile RA and psoriasis, and is presently under FDA review.

The drug is intended to improve bioavailability and overcome tolerability issues associated with today's oral MTX therapies. The firm aims to offer the product in ten dosage strengths, ranging from 7.5mg to 30mg in 2.5mg increments.